Get notified when TRAW files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (worsened) — Going-concern disclosure now explicitly states insufficient cash for 12 months post-filing, versus 'more than one year' in baseline—a worsening liquidity outlook.
- Material Weakness (improved) — Previously-disclosed material weakness in internal controls has been remediated through implementation of formal risk assessment and segregation of duties.
Traws reports going-concern warning, Symbio termination, and Phase 2 COVID data
Filed April 15, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 31, 2025 · ~1 min read
Key Changes
-
high
Cash fell to $3.8M at year-end (from $21.3M), triggering explicit going-concern disclosure. April 2026 financing raised $10M upfront with $50M in milestone-contingent warrants that may never be exercised.
MD&A: Liquidity verify on EDGAR → -
high
Company terminated its only revenue-generating collaboration (Symbio) in April 2025, recognizing remaining $2.7M deferred revenue immediately. No further Symbio revenue will be recognized.
MD&A: Revenue verify on EDGAR → -
high
Phase 2 COVID trial for ratutrelvir completed enrollment; interim data showed no viral rebound (vs. rebound in PAXLOVID arm) and faster symptom resolution. First clinical efficacy signal for the asset.
MD&A: Clinical Development verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (CAG 10-K) is open in full — no account needed.
Partner
Trade TRAW commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify